Contrasting of Proteon Therapeutics Inc. (PRTO) and Myovant Sciences Ltd. (NYSE:MYOV)

Both Proteon Therapeutics Inc. (NASDAQ:PRTO) and Myovant Sciences Ltd. (NYSE:MYOV) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Proteon Therapeutics Inc. N/A 0.00 20.73M -1.19 0.00
Myovant Sciences Ltd. N/A 0.00 246.79M -3.80 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Proteon Therapeutics Inc. and Myovant Sciences Ltd.


Table 2 provides Proteon Therapeutics Inc. and Myovant Sciences Ltd.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics Inc. 0.00% -293.7% -61%
Myovant Sciences Ltd. 0.00% -451.3% -153.5%


Proteon Therapeutics Inc. has a Current Ratio of 10.7 and a Quick Ratio of 10.7. Competitively, Myovant Sciences Ltd.’s Current Ratio is 3.5 and has 3.5 Quick Ratio. Proteon Therapeutics Inc.’s better ability to pay short and long-term obligations than Myovant Sciences Ltd.

Analyst Recommendations

The Ratings and Recommendations for Proteon Therapeutics Inc. and Myovant Sciences Ltd. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Proteon Therapeutics Inc. 0 1 3 2.75
Myovant Sciences Ltd. 0 0 0 0.00

Proteon Therapeutics Inc. has an average price target of $4.33, and a 34.47% upside potential.

Institutional and Insider Ownership

The shares of both Proteon Therapeutics Inc. and Myovant Sciences Ltd. are owned by institutional investors at 69.3% and 30.3% respectively. Insiders owned 1.1% of Proteon Therapeutics Inc. shares. Comparatively, insiders own roughly 0.1% of Myovant Sciences Ltd.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Proteon Therapeutics Inc. -2.43% 4.07% 62.43% 14.69% 22.17% 23.79%
Myovant Sciences Ltd. 6.05% 24.62% 20.95% 1.37% 57.94% 40.04%

For the past year Proteon Therapeutics Inc. has weaker performance than Myovant Sciences Ltd.


Proteon Therapeutics Inc. beats on 6 of the 7 factors Myovant Sciences Ltd.

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.